证券代码： 300765 证券简称： 新诺威 石药创新制药股份有限公司投资者关系活动记录表 编号：2025-04 4、经营性现金流净流出 12.35 亿元，但仍有 4.55 亿元 闲置资金用于理财。在创新药研发投入需持续加码的背景 下，如何平衡短期资金收益与长期研发需求的资源分配？ 您好，感谢您的关注。公司理财资金主要投资于低风险、 流动性高的现金管理类产品，是在不影响研发、生产等经营 活动的前提下，有效管理资金，尽可能的获取一定的资金收 益，有利于公司的长期发展和全体股东利益。谢谢！ 5、姚总好，现在公司创新药研发需要大量资金，请问 公司如何平衡收入与投入？公司何时可以转亏为盈？公司 对未来发展有何计划？谢谢。 您好，感谢您的关注。资金投入是研发创新的基础，作 为我国生物医药行业的重要创新主体，公司将一如既往的坚 持资金投入，保障各项创新活动的正常开展。公司作为 A 股 上市公司，融资渠道通畅，咖啡因等功能性原料业务给公司 带来了较为充沛的现金流，能够保障现有研发活动的正常开 展。未来随着各项创新管线的不断兑现，将进一步为公司研 发以及长期发展提供支撑。公司未来将继续坚定向创新药转 型的发展方向，以科技创新 ...

9月15日，新诺威参与2025年河北辖区上市公司投资者网上集体接待日。期间管理层介绍，公司目前没 有GLP-1相关产品。 公司功能原料业务收入下降主要原因为咖啡因价格较2022年及2023年高位回落，目前咖啡因价格基本稳 定，该业务分部仍保持较高的盈利水平。 此外，公司SYS6010产品研发进展顺利，具体情况如下：1.EGFR突变TKI耐药的非小细胞肺癌的3期临 床研究已经于今年3月在国内正式启动，目前正在入组中；2.海外研发进展推进顺利；3.同步探索开展多 个联合用药探索研究，覆盖食管鳞癌，小细胞肺癌，EGFR突变型和野生型非小细胞肺癌一线患者。4. 今年H2没有数据发布计划，预计明年会有数据更新读出。 公司恩朗苏拜单抗已纳入医保，商业化正常开展中。在研发方面，目前正在开展一线复发或转移性宫颈 癌关键临床试验；2025年6月，在中国开展的用于小细胞肺癌放化疗后巩固治疗的II/III期临床试验，实 现首例受试者入组。同时公司也在探索pd-1联用公司SYS6010（EGFR-ADC)产品的相关试验。 （企业业绩说明会） ...

Group 1: Production and Market Strategy - The company has a caffeine production capacity of 16,700 tons/year, with a sales volume of 14,010 tons in 2023. It aims to enhance gross margins through product structure upgrades and explore new application fields such as medical beauty and pet health [1] - The company is committed to maintaining its competitive edge in the functional raw materials industry by expanding into niche products like theobromine and theophylline, leveraging its production advantages to create a diversified profit engine [1] Group 2: Research and Development - The company emphasizes innovation and R&D as core drivers for future growth, focusing on aligning product development with market demand to mitigate the high failure rates and costs associated with drug development [2] - Significant resources are being allocated to accelerate product layout and R&D progress, with a goal to solidify and expand its innovative biopharmaceutical platform [2] Group 3: Financial Performance and Shareholder Information - As of April 10, 2025, the number of shareholders is 10,386 [4] - The company plans to disclose its Q1 2025 report on April 24, 2025, and has already released its 2024 annual report on March 21, 2025 [4] Group 4: Market Impact and Risk Management - The direct revenue from the U.S. market is low, and the current tariff policies have minimal direct impact on the company's profitability, indicating manageable risk [4] - The company is actively monitoring changes in international trade policies to address potential risks [4] Group 5: Product Development and Sales - The company is in the process of commercializing the innovative drugs Enlansumab and Omabuzumab, which have been approved for inclusion in the medical insurance directory [5] - The sales network for these products is being developed systematically [5]